A double-blind, randomized, placebo-controlled phase II trial enrolling patients with rapidly progressive SOD1-mutant ALS suggested a possible therapeutic benefit of arimoclomol [83]. Here, SOD1 is linked to amyotrophic lateral sclerosis.